VIDEO: Heated debate over immunotherapy combinations at lung cancer meeting

ByMarley V. Ghizzone

In this video, Roy S. Herbst, MD, PhD, Yale Cancer Center and Smilow Cancer Hospital, discussed a session of this year’s International Lung Cancer Congress focused on immunotherapy.

According to Herbst, a heated debated cropped up around the use of immunotherapy, whether alone, in combination with other immunotherapy or with chemotherapy.

“We’re going to have to start personalizing immunotherapy,” he said. “Right now, for most patients, chemo-immunotherapy is the regimen of choice.”

References:

Ramalingam SS, et al. Abstract 9500. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interview

Disclosures: Herbst reports receiving research support from AstraZeneca, Eli Lilly and Company, Genentech/Roche and Merck and Company, and serving as a board member for Junshi Pharmaceuticals and as a consultant for Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol‐Myers Squibb, Cybrexa, Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme, Heat Biologics, IMAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen and WindMIL Therapeutics.

Take Homes in Lung Cancer

Read more

VIDEO: Heated debate over immunotherapy combinations at lung cancer meeting

References:

Related Content